Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 10/20 | 0.59 |
| ▸ | PIK3CD | O00329 | 9/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.59 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 8/20 | 0.48 |
| ▸ | CA12 | O43570 | 7/20 | 0.48 |
| ▸ | CA9 | Q16790 | 7/20 | 0.48 |
| ▸ | CA1 | P00915 | 5/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2640554 | 0.87 | PIK3CG (0.72) | PIK3CGPIK3CDPIK3CAPIK3CB | |
| SCHEMBL936874 | 0.85 | PIK3CG (0.59) | PIK3CGPIK3CDPIK3CAPIK3CBCA2 | |
| SCHEMBL936393 | 0.84 | PIK3CG (0.80) | PIK3CGPIK3CDPIK3CAPIK3CB | |
| SCHEMBL614711 | 0.79 | RET (0.61) | PIK3CGPIK3CDPIK3CAPIK3CB | |
| SCHEMBL12909565 | 0.78 | PIK3CG (0.50) | PIK3CGPIK3CDPIK3CAPIK3CB | |
| SCHEMBL27038303 | 0.76 | PIK3CG (0.63) | PIK3CGPIK3CDPIK3CAPIK3CB | |
| Hydrochloric Acid SCHEMBL933897 | 0.76 | PIK3CG (0.49) | PIK3CGPIK3CDPIK3CAPIK3CB | |
| SCHEMBL1932766 | 0.76 | PIK3CG (0.49) | PIK3CGPIK3CDPIK3CAPIK3CB | |
| SCHEMBL936107 | 0.75 | PIK3CG (0.72) | PIK3CGPIK3CDPIK3CAPIK3CB | |
| SCHEMBL936625 | 0.74 | PIK3CG (1.00) | PIK3CGPIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222674-B1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LTD (GB) | 2015-11-11 | — | — | EP | claimed |
| US-8865699-B2 | Amino triazoles as PI3K inhibitors | CELLZOME LTD. (GB) | 2014-10-21 | — | — | US | claimed |
| US-20110021497-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LIMITED (GB) | 2011-01-27 | — | — | US | claimed |
| EP-2222674-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | Cellzome Limited (GB) | 2010-09-01 | — | — | EP | claimed |
| WO-2009068482-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LIMITED (GB) | 2009-06-04 | — | — | WO | claimed |
| EP-2222674-B1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LTD (GB) | 2015-11-11 | — | — | EP | disclosed |
| EP-2222674-B1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LTD (GB) | 2015-11-11 | — | — | EP | disclosed |
| US-8865699-B2 | Amino triazoles as PI3K inhibitors | CELLZOME LTD. (GB) | 2014-10-21 | — | — | US | disclosed |
| US-8865699-B2 | Amino triazoles as PI3K inhibitors | CELLZOME LTD. (GB) | 2014-10-21 | — | — | US | disclosed |
| US-8865699-B2 | Amino triazoles as PI3K inhibitors | CELLZOME LTD. (GB) | 2014-10-21 | — | — | US | disclosed |
| US-20110021497-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LIMITED (GB) | 2011-01-27 | — | — | US | disclosed |
| US-20110021497-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LIMITED (GB) | 2011-01-27 | — | — | US | disclosed |
| US-20110021497-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LIMITED (GB) | 2011-01-27 | — | — | US | disclosed |
| EP-2222674-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | Cellzome Limited (GB) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009068482-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LIMITED (GB) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009068482-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | CELLZOME LIMITED (GB) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021497-A1 | AMINO TRIAZOLES AS PI3K INHIBITORS | PIK3C3, PIK3R3, PIK3R5 | PIK3CG 11/4885PIK3CD 6/4885PIK3CA 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.